Skip to main content
Article thumbnail
Location of Repository

Medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis

By Tetyana Moshkovska


5-aminosalycilic acid (5-ASA) therapy is effective for maintaining remission in patients with ulcerative colitis (UC) and may also reduce colorectal cancer risk. However, medication non-adherence is a known barrier to the effectiveness of prescribed regimes and there is a lack of evidence about methods of improving adherence to 5-ASA treatment. This research programme addressed the hypothesis that adherence can be improved by a multi-faceted intervention tailored to individual patient needs.\ud A qualitative study identified that important determinants of adherence to 5-ASA medication are: information provided, patient beliefs and the patient-clinician relationship. Adherence can change over time; the study highlighted the need for reinforcement and the fact that health care professionals have a crucial role to play in this dynamic.\ud A cross-sectional study confirmed the difficulty of accurately assessing medication adherence. The two measures used (self-report and urine analysis) were not correlated, phi correlation 0.029 (p = 0.725). Logistic regression identified a significant association between self-reported non-adherence and: younger age [OR for increased age 0.954, 95% CI 0.932–0.976] and also doubts about personal need for medication (OR for BMQ – Specific Necessity scores 0.578, 95%CI 0.366–0.913). For non-adherence based on urine analysis, only South Asian ethnicity was independently associated with non-adherence (OR 2.940, 95%CI 1.303–6.638).\ud A randomised controlled trial showed that a multi-faceted, tailored intervention (including an opportunity for patients to select reminder devices from a range offered) had a significant positive impact on maintaining adherence levels in the intervention group (p=0.001), with a 44% difference between adherence levels in the two groups at follow-up. Changes in questionnaire scores suggested a positive effect of the intervention on satisfaction with information (p<0.001). The intervention was feasible, and was acceptable to patients. The multi-faceted approach studied has potential for implementation in routine care for enhancing persistence with 5-ASA and thus improving patient outcomes

Publisher: University of Leicester
Year: 2011
OAI identifier:

Suggested articles


  1. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study.
  2. (1996). 5-aminosalicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther
  3. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
  4. (2005). 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? Digest Liver Dis
  5. (2005). A case-control study of 5-aminosalycilic acid therapy in the prevention of colitis-related colorectal cancer. DDW; abstract M1052. Gastroenterol.
  6. (2001). A case-matched study of laparoscopic proctocolectomy and ileal pouch-anal anastomosis (PC-IPAA) versus open PC-IPAA for ulcerative colitis (UC). Digestive Disease Week
  7. A comparison of two bedside tests for the detection of salicylates in urine.
  8. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of newonset diabetes mellitus.
  9. a new Sulfanilamide preparation. A. Therapeutic results in rhematiod polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulphanilamide preparations.
  10. A novel salicylic acid optical fibre probe fabrication.
  11. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
  12. A purposeful approach to the constant comparative method in the analysis of qualitative interviews.
  13. (1997). A qualitative study of medication-taking behaviour in primary care. Fam Pract
  14. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease.
  15. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
  16. A systematic review of the associations between dose regimens and medication compliance.
  17. (1972). A theory of Pavlovian conditioning. Variations in effectiveness of reinforcement and non-reinforcement.
  18. A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma.
  19. (2006). adherence and compliance in medicine taking: A conceptual map and research priorities. london: National co-ordinating centre for NHS service delivery and organisation NCCSDO.
  20. Adherence devices in a community sample: How are pillboxes used?
  21. (2003). Adherence to long-term therapies: Evidence for action. world health organization report.
  22. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication.
  23. (1998). Adherence to medication: a review of existing research.
  24. (2010). Adherence to pediatric medical regimens. 2nd ed.
  25. (2005). Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig
  26. Adherence with 5-aminosalicylic acid therapy: Results from a large UK pharmacy database.
  27. (2009). adherence: Involving patients in decisions about prescribed medicines and supporting adherence. National Institute for Clinical Excellence. Clinical guidelines 76.
  28. (1990). An epidemiologic study of inflammatory bowel disease in Rochester, New York. Hospital incidence.
  29. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area.
  30. An experiment to determine the active therapeutic moiety of sulphasalazine.
  31. (1999). An intervention study to enhance medication compliance in community-dwelling elderly individuals.
  32. (2000). An intervention to promote family teamwork in diabetes management task: relationships among parental involvement, adherence to blood glucose monitoring, and glycemic control in young adolescents with type 1 diabetes.
  33. Appendix 16: Informational leaflet for patient Appendix 17: Informational leaflet for relatives or friends Appendix 19: Visual medication reminders for fridges and bedside cabinets
  34. (2000). Assessing perception of medication: psychological perspectives.
  35. Assessment of a patient information booklet on ulcerative colitis.
  36. (1985). Aufses AH. Differences in pathogenesis, incidence and outcome of perforation in inflammatory bowel disease. Surg Gynecol Obstet
  37. (1990). Basics of qualitative research: Grounded theory procedures and techniques.
  38. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: A comparison between patients of South Asian and White British origin.
  39. Better physicianpatient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection.
  40. Cancer morbidity in ulcerative colitis.
  41. Cancer risk in patients with inflammatory bowel disease: a population-based study.
  42. (2007). Challenges and strategies of children and adolescents with inflammatory bowel disease: A qualitative examination. Health Qual Life Outcomes
  43. (2007). Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population-based study from Copenhagen, Denmark. Inflamm Bowel Dis
  44. Changes in the incidence of inflammatory bowel disease: what does it mean?
  45. (1998). Classical conditioning. In:
  46. (1989). Classification of inflammatory bowel disease.
  47. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.
  48. Clinical outcome of the first ten years of ulcerative colitis and proctitis.
  49. (1993). Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci
  50. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
  51. (2000). Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther
  52. (1992). Colorectal cancer risk and mortality in patients with ulcerative colitis.
  53. Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.
  54. (1997). Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
  55. Compliance to therapy in patients on a maintenance dose of sulfasalazine.
  56. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130(Suppl 1):65S-72S.
  57. Concurrent and predictive validity of a self-reported measure of medication adherence.
  58. (1960). Conditioned Reflexes: An Investigation of the Physiological Activity of the Cerebral Cortex. The 1960 edition is an unaltered republication of the 1927 translation by Oxford
  59. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis.
  60. Cortisone and corticotrophin in ulcerative colitis.
  61. Cortisone in ulcerative colitis; final report on a therapeutic trial.
  62. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
  63. Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study.
  64. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence.
  65. Der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: Results from a patient-empowerment stud Digestion 2y.
  66. (2005). Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis
  67. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.
  68. (2008). Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ
  69. Development of salicylic acid detector tube. Chudoku kenkyu (The Japanese journal of toxicology)
  70. Development of salicylic acid dipstick test. Chudoku kenkyu (The Japanese journal of toxicology)
  71. Diabetes in adolescence: effects of multifamily group intervention and parent simulation of diabetes.
  72. (2007). Diagnostics of inflammatory bowel disease. Gastroenterol
  73. (1991). Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications.
  74. Discussion on Ulcerative Colitis.
  75. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
  76. (1990). Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
  77. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
  78. Distribution studies of salicylazosulfapyridine and its metabolites.
  79. (1991). Editorial: The role of educational videos in gastroenterology.
  80. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
  81. Effect of information leaflets on knowledge in patients with gastrointestinal diseases.
  82. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
  83. (2007). Effective chronic disease management: Patients' perspectives on medication-related problems. Patient Educ Couns
  84. (1998). Effectiveness of Interventions to Improve Patient Compliance: A Meta-Analysis. Med Care
  85. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial.
  86. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.
  87. Emergency surgery of fulminant ulcerative colitis and toxic megacolon.
  88. Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer.
  89. (1992). Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire.
  90. Epidemiology of Crohn's Disease and Ulcerative Colitis in a Central Canadian Province: A Population-based Study.
  91. Epidemiology of IBD during the twentieth century: an integrated view.
  92. (1997). Epidemiology: smoking and oral contraception.
  93. (1994). Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene.
  94. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications.
  95. (1998). Exercise and the maintenance of weigt loss: 1-year follow-up of controlled clinical trial.
  96. (1990). Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study.
  97. (2009). Factors affecting persistence with masalamine therapy: Results from a large pharmacy database.
  98. Factors associated with nonadherence to oral medication for inflammatory bowel disease: a systematic review.
  99. Factors that affect medication compliance in inflammatory bowel disease.
  100. (1993). Failure of colonoscopic surveillance in ulcerative colitis.
  101. (2000). Framework for design and evaluation of complex interventions to improve health. BMJ
  102. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases.
  103. (1997). Genetics of inflammatory bowel disease.
  104. genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
  105. Geographic origins of Jewish patients with inflammatory bowel disease.
  106. Girls connect: effects of a support group for teenage girls with inflammatory bowel disease and their mothers.
  107. (1994). Grounded Theory methodology: An overview.
  108. Guided self-management and patient-directed follow-up of ulcerative colitis: A randomised trial.
  109. (1991). High performance liquid chromatographic assay of 5-aminosalicylic acid (5-ASA) and its metabolites N-beta-D-glucopyranosyl-5-ASA, N-acetyl-5-ASA, N-formyl-5-ASA and N-butyryl-5-ASA in biological fluids.
  110. (1992). Illness cognitions: using commonsense to understand treatment adherence and affect cognition interactions. Cognit Ther Res
  111. Improved patients compliance through use of a daily drug reminder chart.
  112. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative.
  113. Improving medication adherence in chronic cardiovascular disease.
  114. (2001). Improving patient adherence: state of the art, with a special focus on medication taking for cardiovascular disorders. In:
  115. Incidence of idiopathic ulcerative colitis in Jewish population subgroups in the Beer Sheva region of Israel.
  116. (1996). Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD).
  117. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom.
  118. Increasing patient adherence to gastroenterology treatment and prevention regimens.
  119. (1997). Inflammatory bowel disease and cancer.
  120. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.
  121. Inflammatory bowel disease in Hubei Province of China.
  122. (2000). Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther
  123. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-S9.
  124. Inflammatory bowel disease: Patients' expectations in the 1990s.
  125. (1999). Inflammatory bowel disease. 3: importance of partnership in care.
  126. (1935). Inflammatory colon disease in
  127. (1997). Information for patients about inflammatory bowel disease.
  128. (1988). Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment.Pharmacol.Ther.
  129. (2005). Interventions for enhancing medication adherence. [Update of Syst Rev.
  130. (2002). Interventions for helping patients to follow prescriptions for medications. Cochrane Library.
  131. Interventions to enhance medication adherence in chronic medical conditions: a systematic review.
  132. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.
  133. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs.
  134. (1989). Introduction of information during the initial medical visit: Consequences for patient follow-through with physician recommendations for medication. Soc Sci Med
  135. (1998). Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study.
  136. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med
  137. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?
  138. Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis? Inflamm Bowel Dis 2008;14(Suppl 2):S2-S3.
  139. (2002). Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. Aliment Pharmacol Ther
  140. Liver and gut mucosa acetylation of mesalazine in healthy volunteers.
  141. Long term prognosis in ulcerative colitis--based on results from a regional patient group from the county of Copenhagen.
  142. (2002). Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a crosssectional survey. Aliment Pharmacol Ther
  143. (2002). Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Digest Liver Dis
  144. (1996). Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.
  145. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
  146. Maintenance therapy in ulcerative colitis and Crohn's disease.
  147. Maternal correlates of health status in adolescents with inflammatory bowel disease.
  148. (1999). Medical therapy for inflammatory bowel disease.
  149. Medication Adherence and Quality of Life in Pediatric Inflammatory Bowel Disease.
  150. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study.
  151. Medication non-adherence is associated with increased medical health care costs.
  152. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
  153. Medication nonadherence: Finding solutions to a costly medical problem.
  154. (2009). Medication persistence in patients with ulcerative colitis: Meeting the challenges and improving patient outcomes. MedscapeCME Gastroenterol.
  155. (2006). Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Digest Dis Sci
  156. (1999). Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.
  157. (1993). Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
  158. Meta-analysis of trials of interventions to improve medication adherence.
  159. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
  160. Morbid appearance in the intestines of Miss Bankes.
  161. (1970). Mortality among patients with ulcerative colitis:
  162. (1993). Mortality in patients with ulcerative colitis in Leicestershire, 1972-1989. An epidemiological study. Digest Dis Sci
  163. Mortality in ulcerative colitis.
  164. Moxon W editors.
  165. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
  166. Nonadherence in inflammatory bowel disease: Results of factor analysis.
  167. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.
  168. Not to be taken as directed : Putting concordance for taking medicines into practice.
  169. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease.
  170. On simple ulcerative colitis and other intestinal ulcers. Guy’s hospital reports.
  171. Optimizing adherence to pharmaceutical care plans.
  172. Oral medication adherence in pediatric inflammatory bowel disease.
  173. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies.
  174. (1991). Overview of methods to measure and enhance patient compliance.
  175. (1975). Pathology of ulcerative colitis.
  176. (1992). Patient compliance - an overview.
  177. Patient nonadherence to medication in inflammatory bowel disease.
  178. Patient-reported compliance with 5-ASA drugs in inflammatory bowel disease: A multi-national study.
  179. Patient's attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease.
  180. (2006). Patients and health professionals' perspectives on the sociocultural influences on secondary cardiac behaviour: A qualitative study of the implications in policy and practice. Fam Pract
  181. (1999). Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.
  182. Patients' perceptions of information received about medication prescribed for bipolar disorder: implications for informed choice.
  183. Patients' perceptions of nurses' skill.
  184. Patients’ perception of information about HAART: Impact on treatment decisions.
  185. (1990). Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther
  186. Pharmacology of olsalazine.
  187. Physicianpatient relationship and medication compliance: A primary care investigation.
  188. (2007). Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis
  189. Pillboxes and antiretroviral adherence: prevalence of use, perceived benefits, and implications for electronic medication monitoring devices.
  190. (2009). Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol
  191. PPAR[gamma] as a new therapeutic target in inflammatory bowel diseases.
  192. (1998). Predicting treatment adherence: an overview of theoretical models.
  193. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.
  194. Predictors of medication adherence in inflammatory bowel disease.
  195. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther
  196. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations.
  197. predictors, and clinical consequences of medical adherence in IBD: how to improve it?
  198. Prednisolone as maintenance treatment for ulcerative colitis in remission.
  199. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England.
  200. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
  201. Prevalence of ulcerative colitis and Crohn's disease in Japan.
  202. Preventing neoplastic progression in ulcerative colitis.
  203. (1998). Preventing relapse and maintaining change in addictive behaviors. Clin Psychol Sci Pract
  204. Primary care: chemoprevention of colorectal cancer.
  205. Primary medication adherence in a rural population: The role of the patient-physician relationship and satisfaction with care.
  206. (2003). Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease (IBD): A large british epidemiological study.
  207. Proceedings: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine
  208. (1998). Prospective memory and medicine-taking.
  209. (2001). Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: Results from a 20-year surveillance study. Dis Colon Rectum
  210. (1994). Qualitative data analysis for applied policy research.
  211. Qualitative research in health care. Analysing qualitative data.
  212. Rapid determination of salicylate in biological fluids.
  213. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down?
  214. (1999). Rectal and colonic mesalazine concentration-in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther
  215. Reinstatement of an operant response by the delivery of reinforcement during extinction.
  216. (1985). Relapse Prevention: Maintenance strategies in the treatment of addictive behaviors.
  217. (1997). Representations of medication and treatment: advances in theory and measurement.
  218. Resisting medicines: a synthesis of qualitative studies of medicine taking.
  219. Reversible male infertility due to sulphasalazine: studies in man and rat.
  220. Review article: 5-Aminosalicylate formulations for the treatment of ulcerative colitis - Methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther
  221. (2004). Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther
  222. (2006). Review article: How to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther
  223. (2007). Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther
  224. (2008). Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther
  225. (1997). Review article: the management of severe ulcerative colitis. Aliment Pharmacol Ther
  226. Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts. Aliment Pharmacol Ther
  227. Review: Current trends in inflammatory bowel disease: The natural history.
  228. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther
  229. (1996). Risk factors of colorectal cancer in inflammatory bowel disease.
  230. Satisfaction with information and its relationship with adherence in patients with chronic pain.
  231. Severity of Inflammation Is a Risk Factor for Colorectal Neoplasia in Ulcerative Colitis.
  232. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies.
  233. Social and emotional support and its implication for health.
  234. (1996). Social network, social support and coping with serious illness: The family connection. Soc Sci Med
  235. Social relationships and health.
  236. Social support and health: a review of physiological processes potentially underlying links to disease outcomes.
  237. (1990). Social support for women during chronic illness: the relationship among sources and types to adjustment. Res Nurs Health
  238. Statistics of ulcerative colitis from London hospitals.
  239. (2003). Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther
  240. (1983). Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digest Dis Sci
  241. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.
  242. Suppression of NFkappaB activity by sulfasalazine is mediated by direct inhibition of I-kappaB kinases alpha and beta.
  243. Survey of patient and physician assessment of a compliance reminder device in the treatment of hypertension.
  244. (2008). Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom
  245. Systematic review: adherence issues in the treatment of ulcerative colitis.
  246. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
  247. (1996). Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
  248. The beliefs about medicines questionnaire : the development and evaluation of a new method for assessing the cognitive representation of medication.
  249. (1998). The benefits of patient education.
  250. The course and prognosis of ulcerative colitis.
  251. The distribution of ulcerative colitis and regional enteritis in United States veterans with particular reference to the Jewish religion.
  252. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther
  253. (1997). The effect on compliance of a health education leaflet in colorectal cancer screening in general practice in central England.
  254. The effects of a psychiatric patient education to medication program on post-discharge compliance.
  255. (2006). The effects of pharmacist intervention on depression. medication adherence: A systematic review. A pharmacy practice paper.
  256. The emergence of inflammatory bowel disease in the Asian Pacific region.
  257. The epidemiologic evidence for a relationship between social support and health.
  258. (1991). The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterol
  259. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey.
  260. The incidence and prevalence of inflammatory bowel disease in North Tees Health District.
  261. (1987). The information needs and fears of patients with inflammatory bowel disease. Hepatogastroenterology
  262. (1996). The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.
  263. (1995). The pharmacology of anti-inflammatory drugs in inflammatory bowel disease.
  264. The physician's actions and the outcome of illness in family practice.
  265. The prognosis of idiopathic proctitis.
  266. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
  267. (2001). The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Saf Health Care
  268. (1999). The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Aliment Pharmacol Ther
  269. (1991). The theory of planned behavior.
  270. The treatment of 124 cases of ulcerative colitis with salazopyrin. Attempts at desensitization in cases of hypersensitiveness to sulphasalazine.
  271. (2005). Theory of Planned Behaviour and Health Behaviour. In:
  272. (1990). Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man. Aliment Pharmacol Ther
  273. (2009). Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther
  274. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr.
  275. Treatment of ulcerative colitis with salicylazosulphapyridine.
  276. (2003). Treatment perceptions and self regulation. In:
  277. (1998). Trinder's bedside test for qualitative determination of salicylate ingestions.
  278. (2006). Ulcerative Colitis and Clinical Course: Results of a 5-Year Population-based Followup Study (The IBSEN Study). Inflamm Bowel Dis
  279. (1998). Ulcerative colitis and colon cancer: more controversy than clarity. Dig Dis
  280. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking.
  281. Ulcerative colitis: diagnosis and management. Case study and commentary.
  282. (1921). Ulcerative colitis. Guy’s hospital report.
  283. (2010). Ulcerative colitis. Orphanet encyclopedia. 2003; Available at: 1.
  284. Ulcerative pancolitis predicts the need for colectomy: Study of an incident cohort of patients with ulcerative colitis in Aragon (Spain).
  285. (1991). Ulcerative proctitis in central Sweden 1965-1983. A population-based epidemiological study. Dig Dis Sci
  286. Understanding medication non-adherence in bipolar disorders using a Necessity-Concerns Framework.
  287. Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.
  288. (1995). Urine trinder spot test: A rapid salicylate screen for the emergency department. Ann Emerg Med
  289. (2003). Use of 5-ASA is associated with a decrease risk of dysplasia and colon cancer (CRC) in ulcerative colitis
  290. Use of ferric chloride to identify salicylate-containing poisons.
  291. Use of the Urine Color Test to Monitor Compliance With Isoniazid Treatment of Latent Tuberculosis Infection.
  292. Using email and text messaging to improve patient compliance with blood monitoring.
  293. (1992). What do patients want to know about their inflammatory bowel disease?
  294. Why People Use Health Services.&quot;.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.